Socioeconomic inequalities and trends in self-reported hypertension and antihypertensive medication use in Australia between 2009 and 2021: a nationwide population-based cohort study.

IF 4.6 2区 医学 Q1 PERIPHERAL VASCULAR DISEASE
Berhe W Sahle, Dianna J Magliano, Andre M N Renzaho, Christopher M Reid, Mark R Nelson, Sandra Nolte, Richard Ofori-Asenso
{"title":"Socioeconomic inequalities and trends in self-reported hypertension and antihypertensive medication use in Australia between 2009 and 2021: a nationwide population-based cohort study.","authors":"Berhe W Sahle, Dianna J Magliano, Andre M N Renzaho, Christopher M Reid, Mark R Nelson, Sandra Nolte, Richard Ofori-Asenso","doi":"10.1038/s41440-025-02362-1","DOIUrl":null,"url":null,"abstract":"<p><p>This study examined trends in the proportion of adults with self-reported hypertension and in antihypertensive medication use among community-dwelling Australian adults. We analysed data from a longitudinal panel study, covering four waves: 2009 (n = 8023), 2013 (n = 11,475), 2017 (n = 12,843), and 2021 (n = 14,571) for adults aged 18-74 years. Hypertension and antihypertensive medication use were self-reported. Healthcare subsidy was defined as the possession of a low-income healthcare card, a Pensioner Concession Card, or a Commonwealth Seniors Health Card. Prevalence estimates were age-standardised to the 2016 Australian Census population. The age-standardised prevalence of hypertension remained stable from 2009 to 2021, i.e., 15.7% (95% confidence interval [CI]: 15.1-16.4) in 2009 versus 15.2% (95% CI: 14.6-15.7) in 2021. Antihypertensive medication use increased from 39.4% (95% CI: 37.0-41.7) in 2009 to 46.7% (95% CI: 44.0-49.3) in 2021 (P<sub>for trend</sub>: 0.017). The adjusted prevalence ratios (PR) for hypertension were 1.17 (95% CI: 1.11-1.21) in the 1st (most disadvantaged) Socio-Economic Indexes for Areas (SEIFA) quintiles, compared with the 5th (most advantaged) quintile. The PR for antihypertensive medication use were 1.63 (95% CI: 1.11-1.47) in the 1st quintile compared with the 5th quintile. About 58% to 78% of the increased prevalence of hypertension and antihypertensive medication use related to socioeconomic disadvantage was mediated by healthcare subsidy. The prevalence of hypertension in Australia remained stable between 2009 and 2021. While hypertension drug treatment rates improved over the same period, it remains very low, with less than half of those who reported hypertension receiving antihypertensive medication. Healthcare subsidies improve hypertension detection and treatment, especially in socioeconomically disadvantaged groups.</p>","PeriodicalId":13029,"journal":{"name":"Hypertension Research","volume":" ","pages":""},"PeriodicalIF":4.6000,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hypertension Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41440-025-02362-1","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0

Abstract

This study examined trends in the proportion of adults with self-reported hypertension and in antihypertensive medication use among community-dwelling Australian adults. We analysed data from a longitudinal panel study, covering four waves: 2009 (n = 8023), 2013 (n = 11,475), 2017 (n = 12,843), and 2021 (n = 14,571) for adults aged 18-74 years. Hypertension and antihypertensive medication use were self-reported. Healthcare subsidy was defined as the possession of a low-income healthcare card, a Pensioner Concession Card, or a Commonwealth Seniors Health Card. Prevalence estimates were age-standardised to the 2016 Australian Census population. The age-standardised prevalence of hypertension remained stable from 2009 to 2021, i.e., 15.7% (95% confidence interval [CI]: 15.1-16.4) in 2009 versus 15.2% (95% CI: 14.6-15.7) in 2021. Antihypertensive medication use increased from 39.4% (95% CI: 37.0-41.7) in 2009 to 46.7% (95% CI: 44.0-49.3) in 2021 (Pfor trend: 0.017). The adjusted prevalence ratios (PR) for hypertension were 1.17 (95% CI: 1.11-1.21) in the 1st (most disadvantaged) Socio-Economic Indexes for Areas (SEIFA) quintiles, compared with the 5th (most advantaged) quintile. The PR for antihypertensive medication use were 1.63 (95% CI: 1.11-1.47) in the 1st quintile compared with the 5th quintile. About 58% to 78% of the increased prevalence of hypertension and antihypertensive medication use related to socioeconomic disadvantage was mediated by healthcare subsidy. The prevalence of hypertension in Australia remained stable between 2009 and 2021. While hypertension drug treatment rates improved over the same period, it remains very low, with less than half of those who reported hypertension receiving antihypertensive medication. Healthcare subsidies improve hypertension detection and treatment, especially in socioeconomically disadvantaged groups.

2009年至2021年澳大利亚自我报告的高血压和抗高血压药物使用的社会经济不平等和趋势:一项全国性的基于人群的队列研究
本研究调查了澳大利亚社区居民中自我报告高血压的成年人比例和抗高血压药物使用的趋势。我们分析了一项纵向面板研究的数据,涵盖了四波:2009年(n = 8023)、2013年(n = 11,475)、2017年(n = 12,843)和2021年(n = 14,571)的18-74岁成年人。高血压和抗高血压药物使用情况均为自我报告。保健补贴的定义是拥有低收入保健卡、养恤金领取者优惠卡或联邦老年人保健卡。患病率估计是根据2016年澳大利亚人口普查进行年龄标准化的。从2009年到2021年,年龄标准化高血压患病率保持稳定,即2009年为15.7%(95%置信区间[CI]: 15.1-16.4),而2021年为15.2% (95% CI: 14.6-15.7)。抗高血压药物的使用从2009年的39.4% (95% CI: 37.0-41.7)增加到2021年的46.7% (95% CI: 44.0-49.3)(趋势p值:0.017)。第一(最弱势)地区社会经济指数(SEIFA)五分位数的高血压校正患病率比(PR)为1.17 (95% CI: 1.11-1.21),而第五(最弱势)五分位数的高血压校正患病率比为1.17 (95% CI: 1.11-1.21)。与第5个五分位数相比,第1个五分位数使用降压药的PR为1.63 (95% CI: 1.11-1.47)。与社会经济劣势相关的高血压患病率和降压药使用增加中,约58%至78%是由医疗补贴介导的。2009年至2021年间,澳大利亚的高血压患病率保持稳定。虽然高血压药物治疗率在同一时期有所改善,但仍然很低,只有不到一半的高血压患者接受了抗高血压药物治疗。医疗补贴改善了高血压的检测和治疗,特别是在社会经济弱势群体中。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Hypertension Research
Hypertension Research 医学-外周血管病
CiteScore
7.40
自引率
16.70%
发文量
249
审稿时长
3-8 weeks
期刊介绍: Hypertension Research is the official publication of the Japanese Society of Hypertension. The journal publishes papers reporting original clinical and experimental research that contribute to the advancement of knowledge in the field of hypertension and related cardiovascular diseases. The journal publishes Review Articles, Articles, Correspondence and Comments.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信